| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2023 ( Subtotal = -$138,672 ) |
| | 2023 | 2020 | UNIVERSITY OF NEW SOUTH WALES | HIGH ST | KENSINGTON | | | | AUS | RF1AG057531 | COSMIC: An international consortium to identify risk and protective factors and biomarkers of cognitive ageing and dementia in diverse ethno-racial groups and geographical settings | 000 | 1 | NIH | 10/1/2022 | -$138,672 |
| | 2023 | 2019 | UNIVERSITY OF NEW SOUTH WALES | HIGH ST | KENSINGTON | | | | AUS | R01DA040506 | A randomised study of interferon-free treatment for recently acquired hepatitis C in people who inject drugs and people with HIV coinfection (the REACT Study) | 000 | 5 | NIH | 11/23/2022 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $881,289 ) |
| | 2022 | 2022 | UNIVERSITY OF NEW SOUTH WALES | HIGH ST | KENSINGTON | | | | AUS | R01CA251443 | Engineered microtumor arrays for development of combination therapies | 000 | 3 | NIH | 7/18/2022 | $260,106 |
| | 2022 | 2022 | UNIVERSITY OF NEW SOUTH WALES | HIGH ST | KENSINGTON | | | | AUS | R21AI162141 | Characterisation and harnessing the CD8+ Tissue Resident Memory T cell response in HPV-driven anal neoplasia. | 000 | 2 | NIH | 7/14/2022 | $121,306 |
| | 2022 | 2022 | UNIVERSITY OF NEW SOUTH WALES | HIGH ST | KENSINGTON | | | | AUS | U01CA199000 | NCI Pediatric In Vivo Testing Program - Leukemia | 003 | 7 | NIH | 8/11/2022 | $445,877 |
| | 2022 | 2022 | UNIVERSITY OF NEW SOUTH WALES | HIGH ST | KENSINGTON | | | | AUS | R03CA251976 | Targeted therapy against TERT oncogene-rearranged neuroblastoma | 000 | 2 | NIH | 7/29/2022 | $54,000 |
| | 2022 | 2021 | UNIVERSITY OF NEW SOUTH WALES | HIGH ST | KENSINGTON | NSW | | | AUS | R21AI150331 | Accurately defining the distribution of the genetically intact and potentially replication-competent HIV-1 reservoir during the first 3 years of integrase inhibitor containing antiretroviral therapy | 000 | 2 | NIH | 4/25/2022 | $0 |
| | 2022 | 2021 | UNIVERSITY OF NEW SOUTH WALES | HIGH ST | KENSINGTON | | | | AUS | U01CA199000 | NCI Pediatric In Vivo Testing Program - Leukemia | 000 | 6 | NIH | 10/28/2021 | $20,091 |
| | 2022 | 2021 | UNIVERSITY OF NEW SOUTH WALES | HIGH ST | KENSINGTON | | | | AUS | U01CA199000 | NCI Pediatric In Vivo Testing Program - Leukemia | 001 | 5 | NIH | 10/28/2021 | -$20,091 |
| | 2022 | 2021 | UNIVERSITY OF NEW SOUTH WALES | HIGH ST | KENSINGTON | NSW | | | AUS | U01CA199000 | NCI Pediatric In Vivo Testing Program - Leukemia | 002 | 6 | NIH | 12/8/2021 | $0 |
| | 2022 | 2020 | UNIVERSITY OF NEW SOUTH WALES | HIGH ST | KENSINGTON | NSW | | | AUS | RF1AG057531 | COSMIC: An international consortium to identify risk and protective factors and biomarkers of cognitive ageing and dementia in diverse ethno-racial groups and geographical settings | 001 | 1 | NIH | 1/31/2022 | $0 |
| | 2022 | 2019 | UNIVERSITY OF NEW SOUTH WALES | HIGH ST | KENSINGTON | | | | AUS | R01DA040506 | A randomised study of interferon-free treatment for recently acquired hepatitis C in people who inject drugs and people with HIV coinfection (the REACT Study) | 000 | 5 | NIH | 12/13/2021 | $0 |
| | 2022 | 2019 | UNIVERSITY OF NEW SOUTH WALES | HIGH ST | KENSINGTON | | | | AUS | R01DA044170 | Using existing data to understand and ameliorate risk in opioid agonist therapy | 000 | 3 | NIH | 4/12/2022 | $0 |
| | 2022 | 2017 | UNIVERSITY OF NEW SOUTH WALES | HIGH ST | KENSINGTON | NSW | | | AUS | RF1AG057531 | COSMIC: An international consortium to identify risk and protective factors and biomarkers of cognitive ageing and dementia in diverse ethno-racial groups and geographical settings | 000 | 1 | NIH | 1/31/2022 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $1,226,051 ) |
| | 2021 | 2021 | UNIVERSITY OF NEW SOUTH WALES | HIGH ST | KENSINGTON | NSW | | | AUS | R21AI150331 | Accurately defining the distribution of the genetically intact and potentially replication-competent HIV-1 reservoir during the first 3 years of integrase inhibitor containing antiretroviral therapy | 000 | 2 | NIH | 5/24/2021 | $134,540 |
| | 2021 | 2021 | UNIVERSITY OF NEW SOUTH WALES | HIGH ST | KENSINGTON | NSW | | | AUS | U01CA199000 | NCI Pediatric In Vivo Testing Program - Leukemia | 006 | 5 | NIH | 8/17/2021 | $0 |
| | 2021 | 2021 | UNIVERSITY OF NEW SOUTH WALES | HIGH ST | KENSINGTON | NSW | | | AUS | U01CA199000 | NCI Pediatric In Vivo Testing Program - Leukemia | 001 | 5 | NIH | 2/3/2021 | $192,309 |
| | 2021 | 2021 | UNIVERSITY OF NEW SOUTH WALES | HIGH ST | KENSINGTON | NSW | | | AUS | R21AI162141 | Characterisation and harnessing the CD8+ Tissue Resident Memory T cell response in HPV-driven anal neoplasia. | 000 | 1 | NIH | 6/21/2021 | $148,306 |
| | 2021 | 2021 | UNIVERSITY OF NEW SOUTH WALES | HIGH ST | KENSINGTON | NSW | | | AUS | R01CA251443 | Engineered microtumor arrays for development of combination therapies | 000 | 2 | NIH | 6/30/2021 | $241,920 |
| | 2021 | 2021 | UNIVERSITY OF NEW SOUTH WALES | HIGH ST | KENSINGTON | NSW | | | AUS | R03CA251976 | Targeted therapy against TERT oncogene-rearranged neuroblastoma | 000 | 1 | NIH | 7/16/2021 | $54,000 |
| | 2021 | 2021 | UNIVERSITY OF NEW SOUTH WALES | HIGH ST | KENSINGTON | NSW | | | AUS | R03CA251976 | Targeted therapy against TERT oncogene-rearranged neuroblastoma | 001 | 1 | NIH | 9/15/2021 | -$54,000 |
| | 2021 | 2021 | UNIVERSITY OF NEW SOUTH WALES | HIGH ST | KENSINGTON | NSW | | | AUS | U01CA199000 | NCI Pediatric In Vivo Testing Program - Leukemia | 005 | 6 | NIH | 8/17/2021 | $454,976 |
| | 2021 | 2021 | UNIVERSITY OF NEW SOUTH WALES | HIGH ST | KENSINGTON | NSW | | | AUS | R03CA251976 | Targeted therapy against TERT oncogene-rearranged neuroblastoma | 001 | 1 | NIH | 9/15/2021 | $54,000 |
| | 2021 | 2019 | UNIVERSITY OF NEW SOUTH WALES | HIGH ST | KENSINGTON | NSW | | | AUS | U01CA199000 | NCI Pediatric In Vivo Testing Program - Leukemia | 004 | 5 | NIH | 8/17/2021 | $0 |
| | 2021 | 2019 | UNIVERSITY OF NEW SOUTH WALES | HIGH ST | KENSINGTON | NSW | | | AUS | U01CA199000 | NCI Pediatric In Vivo Testing Program - Leukemia | 000 | 5 | NIH | 2/3/2021 | $0 |
| | 2021 | 2019 | UNIVERSITY OF NEW SOUTH WALES | HIGH ST | KENSINGTON | NSW | | | AUS | R21CA226959 | Eradication of MYCN-amplified neuroblastoma by targeting the interaction between a long noncoding RNA and its binding protein | 000 | 2 | NIH | 1/4/2021 | $0 |
| | 2021 | 2018 | UNIVERSITY OF NEW SOUTH WALES | HIGH ST | KENSINGTON | NSW | | | AUS | U01CA199000 | NCI Pediatric In Vivo Testing Program - Leukemia | 003 | 4 | NIH | 7/28/2021 | $0 |
| | 2021 | 2017 | UNIVERSITY OF NEW SOUTH WALES | HIGH ST | KENSINGTON | NSW | | | AUS | U01CA199000 | NCI Pediatric In Vivo Testing Program - Leukemia | 002 | 3 | NIH | 7/27/2021 | $0 |
|
| Issue Date FY: 2020 ( Subtotal = $884,944 ) |
| | 2020 | 2020 | UNIVERSITY OF NEW SOUTH WALES | HIGH ST | KENSINGTON | NSW | 2052 | | AUS | U01CA199000 | NCI Pediatric In Vivo Testing Program - Leukemia | 001 | 5 | NIH | 3/17/2020 | $193,793 |
| | 2020 | 2020 | UNIVERSITY OF NEW SOUTH WALES | HIGH ST | KENSINGTON | NSW | 2052 | | AUS | R01CA251443 | Engineered microtumor arrays for development of combination therapies | 000 | 1 | NIH | 9/9/2020 | $243,896 |
| | 2020 | 2020 | UNIVERSITY OF NEW SOUTH WALES | HIGH ST | KENSINGTON | NSW | 2052 | | AUS | RF1AG057531 | COSMIC: An international consortium to identify risk and protective factors and biomarkers of cognitive ageing and dementia in diverse ethno-racial groups and geographical settings | 002 | 1 | NIH | 4/27/2020 | -$295,969 |
| | 2020 | 2020 | UNIVERSITY OF NEW SOUTH WALES | HIGH ST | KENSINGTON | NSW | 2052 | | AUS | R21AI150331 | Accurately defining the distribution of the genetically intact and potentially replication-competent HIV-1 reservoir during the first 3 years of integrase inhibitor containing antiretroviral therapy | 000 | 1 | NIH | 6/12/2020 | $162,460 |
| | 2020 | 2020 | UNIVERSITY OF NEW SOUTH WALES | HIGH ST | KENSINGTON | NSW | 2052 | | AUS | RF1AG057531 | COSMIC: An international consortium to identify risk and protective factors and biomarkers of cognitive ageing and dementia in diverse ethno-racial groups and geographical settings | 001 | 1 | NIH | 3/31/2020 | $295,969 |
| | 2020 | 2020 | UNIVERSITY OF NEW SOUTH WALES | HIGH ST | KENSINGTON | NSW | 2052 | | AUS | RF1AG057531 | COSMIC: An international consortium to identify risk and protective factors and biomarkers of cognitive ageing and dementia in diverse ethno-racial groups and geographical settings | 002 | 1 | NIH | 4/27/2020 | $295,969 |
| | 2020 | 2019 | UNIVERSITY OF NEW SOUTH WALES | HIGH ST | KENSINGTON | NSW | 2052 | | AUS | U01CA199000 | NCI Pediatric In Vivo Testing Program - Leukemia | 000 | 5 | NIH | 3/17/2020 | $0 |
| | 2020 | 2017 | UNIVERSITY OF NEW SOUTH WALES | HIGH ST | KENSINGTON | NSW | 2052 | | AUS | R01CA172404 | Identifying Prognostic Markers and Therapeutic Targets for Serous Ovarian Cancer | 000 | 5 | NIH | 11/20/2019 | -$11,174 |
| | 2020 | 2017 | UNIVERSITY OF NEW SOUTH WALES | HIGH ST | KENSINGTON | NSW | 2052 | | AUS | RF1AG057531 | COSMIC: An international consortium to identify risk and protective factors and biomarkers of cognitive ageing and dementia in diverse ethno-racial groups and geographical settings | 000 | 1 | NIH | 12/9/2019 | $0 |
|
| Issue Date FY: 2019 ( Subtotal = $1,327,514 ) |
| | 2019 | 2019 | UNIVERSITY OF NEW SOUTH WALES | HIGH ST | KENSINGTON | NSW | 2052 | | AUS | R01DA044170 | Using existing data to understand and ameliorate risk in opioid agonist therapy | 000 | 3 | NIH | 8/27/2019 | $197,617 |
| | 2019 | 2019 | UNIVERSITY OF NEW SOUTH WALES | HIGH ST | KENSINGTON | NSW | 2052 | | AUS | R01DA040506 | A randomised study of interferon-free treatment for recently acquired hepatitis C in people who inject drugs and people with HIV coinfection (the REACT Study) | 000 | 5 | NIH | 6/19/2019 | $572,496 |
| | 2019 | 2019 | UNIVERSITY OF NEW SOUTH WALES | HIGH ST | KENSINGTON | NSW | 2052 | | AUS | R01DA044170 | Using existing data to understand and ameliorate risk in opioid agonist therapy | 001 | 3 | NIH | 8/29/2019 | $48,600 |
| | 2019 | 2019 | UNIVERSITY OF NEW SOUTH WALES | HIGH ST | KENSINGTON | NSW | 2052 | | AUS | R21CA226959 | Eradication of MYCN-amplified neuroblastoma by targeting the interaction between a long noncoding RNA and its binding protein | 000 | 2 | NIH | 6/18/2019 | $121,217 |
| | 2019 | 2019 | UNIVERSITY OF NEW SOUTH WALES | HIGH ST | KENSINGTON | NSW | 2052 | | AUS | R01DA044170 | Using existing data to understand and ameliorate risk in opioid agonist therapy | 002 | 3 | NIH | 9/13/2019 | $0 |
| | 2019 | 2019 | UNIVERSITY OF NEW SOUTH WALES | HIGH ST | KENSINGTON | NSW | 2052 | | AUS | U01CA199000 | NCI Pediatric In Vivo Testing Program - Leukemia | 000 | 5 | NIH | 9/19/2019 | $387,584 |
|
| Issue Date FY: 2018 ( Subtotal = $1,662,503 ) (Continued on the next page) |
| | 2018 | 2018 | UNIVERSITY OF NEW SOUTH WALES | HIGH ST | KENSINGTON | NSW | 2052 | | AUS | R01DA040506 | A randomised study of interferon-free treatment for recently acquired hepatitis C in people who inject drugs and people with HIV coinfection (the REACT Study) | 000 | 4 | NIH | 7/18/2018 | $964,605 |
|
